The clinical question: A 52-year-old male presented to his PCP with rectal bleeding and altered bowel habits in March 2024. He was diagnosed with Stage IIIC colorectal cancer in May 2025 — 14 months later. Would earlier diagnostic workup have identified the cancer at an earlier, more treatable stage?
The trajectory: The patient presented to his PCP (Dr. [Defendant]) on three occasions between March 2024 and January 2025 with rectal bleeding and intermittent diarrhea alternating with constipation. On each visit, the PCP attributed symptoms to hemorrhoids based on external examination and prescribed conservative treatment (fiber, topical hydrocortisone). No digital rectal exam was documented on any visit. No referral to gastroenterology. No colonoscopy ordered. In February 2025, the patient presented to an urgent care facility with worsening symptoms, iron-deficiency anemia (Hgb 9.2), and unintentional weight loss of 18 lbs. The urgent care physician referred him to gastroenterology. Colonoscopy in March 2025 revealed a 4.5 cm mass in the sigmoid colon. Biopsy confirmed adenocarcinoma. Staging CT and PET (April 2025) showed locally advanced disease with regional lymph node involvement: Stage IIIC (T4aN2bM0). He underwent sigmoid colectomy with lymph node dissection in May 2025, followed by adjuvant FOLFOX chemotherapy.
The documented record supports a significant standard-of-care deviation by the defendant PCP. A 52-year-old male presenting with rectal bleeding and altered bowel habits requires, at minimum, a digital rectal exam and referral for colonoscopy — particularly given the patient's age above the USPSTF screening threshold (45+) and lack of prior colonoscopy. Three office visits over 11 months with persistent GI symptoms without colonoscopy referral or even a fecal occult blood test constitutes a failure to pursue an appropriate diagnostic workup.
This timeline isolates the diagnostic decision points where the standard of care required further workup. Red markers indicate deviation points.
Presentation: "Intermittent bright red blood on toilet paper × 3 weeks. Occasional loose stools." PCP action: External visual exam only. Diagnosed "hemorrhoids." Prescribed psyllium fiber and hydrocortisone cream. No DRE performed. No FOBT ordered. No colonoscopy discussed. No family history documented. PCP-001 p.14–15
Presentation: "Rectal bleeding persists, now 2–3x/week. Some diarrhea. Denies weight loss." PCP action: Noted "persistent hemorrhoidal bleeding." Prescribed increased fiber. Recommended sitz baths. Again no DRE. No stool studies. No referral. No colonoscopy. This is the second visit with persistent rectal bleeding in a 52-year-old without colonoscopy workup. PCP-001 p.22–23
Presentation: "Continues to bleed. Now alternating diarrhea and constipation. Reports clothes fitting looser." PCP action: Ordered CBC (results: Hgb 11.8 — low-normal). Continued hemorrhoid diagnosis. No DRE. No colonoscopy referral. No weight documented despite patient reporting apparent weight loss. Hemoglobin trending toward anemia not flagged for further workup. PCP-001 p.31–32
Presentation: Rectal bleeding now daily, fatigue, 18 lb weight loss confirmed. Labs: Hgb 9.2 (iron-deficiency anemia confirmed by ferritin 8, TIBC elevated). Urgent care action: Stat GI referral. GI consult within 5 days. UC-003 p.1–4
Findings: 4.5 cm polypoid mass, sigmoid colon, partially obstructing. Multiple biopsies taken. Pathology: moderately differentiated adenocarcinoma. GI-007 p.3–8
CT chest/abdomen/pelvis and PET: locally advanced sigmoid adenocarcinoma, T4a (serosal invasion), N2b (7/22 lymph nodes positive), M0 (no distant metastasis). Stage IIIC. Sigmoid colectomy with en-bloc lymph node dissection performed May 8, 2025. Adjuvant FOLFOX chemotherapy initiated June 2025. ONC-012, SURG-009
Note: Medisprudence identifies potential standard-of-care issues for attorney evaluation and expert engagement planning. The formal standard-of-care opinion must come from a qualified testifying expert in internal medicine or gastroenterology retained by counsel. This section maps indicators — it does not render an expert opinion.
| Potential Issue | Clinical Basis | Applicable Guideline | Source |
|---|---|---|---|
| Failure to perform DRE | Three visits for rectal bleeding without a single documented digital rectal exam. A DRE is a basic component of the evaluation of rectal bleeding and can identify distal rectal masses, assess for hemorrhoids vs. other pathology, and obtain stool for occult blood testing. | AGA Clinical Practice Guidelines on rectal bleeding evaluation; AAFP recommendations for symptomatic patients | PCP-001 p.14, 22, 31 |
| Failure to refer for colonoscopy | Persistent rectal bleeding in a 52-year-old male (above USPSTF screening threshold) with no prior colonoscopy requires endoscopic evaluation. Three visits over 11 months without referral represents a failure to pursue the appropriate diagnostic workup. The USPSTF recommends colorectal cancer screening for all adults aged 45–75 (Grade A). This patient had never been screened and presented with alarm symptoms. | USPSTF 2021 Screening Recommendation (Grade A for ages 45–75); ACS 2018 Guideline (screening from age 45); ACG Clinical Guidelines on rectal bleeding | PCP-001 |
| Failure to document and investigate weight loss | At Visit 3, the patient reported clothes fitting looser. No weight was recorded. Unintentional weight loss in a patient with persistent GI symptoms is a red-flag finding requiring further investigation. The PCP's failure to document weight and correlate it with the ongoing rectal bleeding represents inadequate clinical assessment. | General internal medicine standard of care for alarm symptoms evaluation | PCP-001 p.31 |
| Failure to evaluate anemia | CBC at Visit 3 showed Hgb 11.8 (low-normal for adult male; reference 13.5–17.5). In the context of persistent rectal bleeding, a hemoglobin of 11.8 should have prompted iron studies and consideration of GI blood loss. By the time the patient reached urgent care 5 weeks later, Hgb had dropped to 9.2 with confirmed iron-deficiency anemia. | AGA guidelines on iron-deficiency anemia in GI patients | PCP-001 p.32, UC-003 p.3 |
Claim: "The patient waited 4 months between Visit 1 and Visit 2, and 6 months between Visit 2 and Visit 3. If symptoms were truly alarming, the patient would have returned sooner or sought a second opinion."
Counter: The PCP diagnosed hemorrhoids and prescribed treatment. The patient reasonably relied on his physician's diagnosis and followed the prescribed treatment plan. The obligation to investigate alarm symptoms rests with the physician, not the patient. The PCP had three opportunities to refer and did not.
Claim: "Colorectal cancer staging is determined at the time of diagnosis. There is no certainty that the cancer was at an earlier stage 14 months prior. Tumor doubling time varies widely."
Counter: This is the primary causation battleground. The testifying oncology expert must address tumor biology and probable staging at the time of the missed diagnostic window. Published literature on sigmoid adenocarcinoma doubling times (mean 130–230 days) supports the position that a tumor diagnosed at Stage IIIC in May 2025 was likely at Stage I–II in early-to-mid 2024. The difference in 5-year survival between Stage I (>90%) and Stage IIIC (~30%) is the damages foundation.
No family history of colorectal cancer documented (note: the PCP also failed to document family history, which is itself a deviation). No prior GI diagnoses. No prior colonoscopy. No inflammatory bowel disease. No genetic predisposition syndromes. BMI 27 (slightly overweight) — not a meaningful defense factor. Non-smoker since 2015.
This section applies the reviewing physician's experience in utilization management and claims review to anticipate the defense medical expert's evaluation framework.
From a medical records review perspective, the defendant's documentation creates an unusually weak defense posture. Specifically:
1. The negative documentation pattern. Three visits for rectal bleeding, and the medical record does not contain a single documented DRE, a single stool guaiac/FIT result, or a single colonoscopy referral discussion. In utilization review and quality audit contexts, the absence of documentation is treated as absence of action. The defense cannot argue "I performed a DRE but didn't document it" without creating a secondary credibility problem.
2. The CBC was ordered but not acted upon. The PCP ordered a CBC at Visit 3 — demonstrating awareness that the clinical picture warranted investigation — but did not follow up on the result (Hgb 11.8, low-normal). In payer quality review, ordering a test and failing to act on an abnormal or borderline result is considered a more serious quality failure than not ordering the test at all, because it demonstrates awareness without action.
3. The weight loss documentation gap. The patient reported perceived weight loss. No weight was recorded. In any payer or hospital quality review, failure to document a measurable vital sign (weight) when the patient spontaneously reports a change would be flagged as a documentation deficiency. Defense will have difficulty explaining why the PCP did not weigh the patient.
Anticipated defense expert strategy: The defense will retain an internist or gastroenterologist who will argue that (a) hemorrhoids are the most common cause of rectal bleeding in this age group, (b) the initial clinical decision to treat conservatively was within the range of reasonable practice, and (c) the causation timeline is speculative because tumor staging at earlier time points cannot be determined with certainty.
The weakness in this defense: Argument (a) is true as a statistical matter — hemorrhoids are common — but it does not justify three visits without endoscopic evaluation in a patient over 45 who has never been screened. Argument (b) may apply to Visit 1 in isolation but fails when applied to the pattern of three visits over 11 months. Argument (c) is the defense's strongest position and requires a well-prepared oncology expert to counter with tumor biology evidence.
Recommendation: Depose the defendant early. The deposition questions should focus on: (1) Why was no DRE performed? (2) What was the differential diagnosis for rectal bleeding at each visit? (3) What guidelines, if any, did the defendant consult? (4) Why was colonoscopy not discussed? (5) What was the significance of the CBC result? These questions will force the defendant to either admit the workup was inadequate or fabricate a clinical rationale that the medical record does not support.
| Element | Recommendation | Rationale |
|---|---|---|
| Standard-of-care expert | Board-certified internist or family medicine physician with active clinical practice | Must practice in the same specialty as the defendant (internal medicine). Illinois requires the expert to practice in the same or similar specialty. Must testify that three visits for persistent rectal bleeding in a 52-year-old without colonoscopy referral falls below the standard of care. Must address the failure to perform DRE and the failure to evaluate the CBC result. |
| Causation expert | Board-certified medical oncologist or colorectal surgeon with colorectal cancer subspecialty experience | Must address the central causation question: what was the probable staging of the tumor 14 months earlier? Must cite published tumor doubling time data for sigmoid adenocarcinoma. Must address the survival differential between Stage I/II (>90% 5-year) and Stage IIIC (~30% 5-year). Must be prepared for Daubert challenge on the staging extrapolation methodology. |
| Damages expert | Consider oncology-focused life care planner | If the claimant has ongoing chemotherapy, surveillance, and quality-of-life impacts, a life care planner can project future medical costs. The key damages theory is the difference in treatment burden: Stage I/II typically requires surgery alone (no chemotherapy) vs. Stage IIIC requiring surgery + 6 months adjuvant FOLFOX + long-term surveillance with increased recurrence risk. |
| Certificate of merit | Illinois requires a Certificate of Merit (735 ILCS 5/2-622) within 90 days of filing | The attorney must have a written report from a physician confirming that there is a reasonable and meritorious cause for filing. This must be from a physician in the same or similar specialty as the defendant. Medisprudence's CMIP does not satisfy this requirement — a formal expert report is needed. |
| Daubert issue | Tumor staging extrapolation methodology | The oncology expert's opinion on probable earlier staging must be based on published tumor doubling time data and epidemiological evidence, not merely clinical experience. The defense will file a Daubert motion to exclude the causation opinion if it relies solely on the expert's subjective assessment. |
| Consider: Berk v. Choy (2026) | If case is in federal court (diversity jurisdiction), state affidavit/certificate requirements may not apply | Per the 2026 Supreme Court decision in Berk v. Choy, state-mandated expert affidavit requirements conflict with FRCP Rule 8 and do not apply in federal diversity cases. If the case is filed in or removed to federal court, the 90-day certificate deadline under Illinois law may not apply. Attorney should verify the filing venue before prioritizing the certificate timeline. |
The medical record documents three missed opportunities to diagnose colorectal cancer over 14 months. The documentation pattern (no DRE, no colonoscopy referral, no weight measurement, incomplete CBC follow-up) creates a strong factual foundation for a malpractice claim. The primary litigation challenge is the causation question — proving what stage the cancer was at 14 months earlier — which requires a well-prepared oncology expert with published tumor biology credentials. The case is recommended for pursuit with expert engagement in both internal medicine (standard of care) and oncology (causation/damages).